- Gilead Sciences Inc (NASDAQ:GILD) has agreed to acquire MiroBio, a privately-held U.K.-based biotechnology company focused on restoring immune balance with agonists targeting immune inhibitory receptors.
- Gilead will pay approximately $405 million in cash.
- The acquisition will provide Gilead with MiroBio’s proprietary discovery platform and the entire portfolio of immune inhibitory receptor agonists.
- Related: Gilead Sciences’ Q2 Beats Street View On Robust Oncology, HIV Product Sales.
- MiroBio’s lead investigational antibody, MB272 has entered Phase 1 clinical trials, with the first patient dosed earlier this week.
- MiroBio’s I-ReSToRE platform has the potential to be used to develop best-in-class agonist antibodies targeting immune inhibitory receptors for inflammatory diseases.
- The company expects the transaction with MiroBio to reduce Gilead’s GAAP and non-GAAP 2022 EPS by approximately $0.30-$0.35.
- Price Action: GILD shares are up 0.42% at $62.01 during the market session on the last check Thursday.
ObsEva Announced Its Shares Will Be Delisted From The Nasdaq Stock Market effective March 23, 2023
ObsEva SA (NASDAQ:OBSV, SIX: OBSN))) today announced that it received a notification letter from The Nasdaq Stock Market LLC ("Nasdaq") on March 14, 2023, advising the Company that its securities are scheduled for delisting from The Nasdaq Capital Market and will be suspended at the opening of U.S. business on March 23, 2023.
